



April 29, 2015

## **Revance Therapeutics to Release First Quarter 2015 Financial Results Wednesday, May 13, 2015**

### **Conference Call Scheduled for Wednesday, May 13, 2015 at 4:30pm ET**

NEWARK, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that the Company will release first quarter 2015 financial results on Wednesday, May 13, 2015 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 22992568; or from the webcast link in the investor relations section of the Company's website at: [www.revance.com](http://www.revance.com).

A replay of the call will be available beginning May 13, 2015 at 4:30pm PT/7:30pm ET through midnight on May 14, 2015. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 22992568. The webcast will be available in the investor relations section on the Company's website for 30 days following the completion of the call.

### **About Revance Therapeutics, Inc.**

Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. Revance is pursuing clinical development for product candidates topical RT001 and injectable RT002 in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at [www.revance.com](http://www.revance.com).

*"Revance Therapeutics", TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.*

CONTACT: Investor Contact

Revance Therapeutics

Jeanie Herbert

(714) 325-3584

[jherbert@revance.com](mailto:jherbert@revance.com)

Westwicke Partners

Leigh Salvo

(415) 513-1281

[leigh.salvo@westwicke.com](mailto:leigh.salvo@westwicke.com)

Trade Media Contact

Nadine Tosk

(847) 920-9858

[nadinepr@gmail.com](mailto:nadinepr@gmail.com)

Source: Revance Therapeutics, Inc.

News Provided by Acquire Media